v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
NET REVENUE        
Clinical Services $ 59,540 $ 55,547 $ 116,511 $ 108,455
Pharma Services 8,206 6,717 14,658 11,238
Total Revenue 67,746 62,264 131,169 119,693
COST OF REVENUE 37,216 34,912 73,336 69,392
GROSS PROFIT 30,530 27,352 57,833 50,301
Operating expenses:        
General and administrative 20,983 18,432 38,050 35,450
Research and development 1,073 947 2,029 1,809
Sales and marketing 7,680 6,132 14,455 11,779
Total operating expenses 29,736 25,511 54,534 49,038
Income from Operations 794 1,841 3,299 1,263
Interest expense, net 1,407 1,411 2,892 2,775
Other expense 124 0 62 0
Income (loss) before taxes (737) 430 345 (1,512)
Income tax expense (benefit) (357) (53) 81 (832)
NET INCOME (LOSS) (380) 483 264 (680)
Deemed dividends on preferred stock 947 929 1,950 1,822
Amortization of preferred stock beneficial conversion feature 1,824 1,710 3,677 3,383
Gain on redemption of preferred stock (9,075) 0 (9,075) 0
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS $ 5,924 $ (2,156) $ 3,712 $ (5,885)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS        
Basic (in dollars per share) $ 0.07 $ (0.03) $ 0.05 $ (0.07)
Diluted (in dollars per share) $ 0.07 $ (0.03) $ 0.04 $ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (in shares) 81,017 79,413 80,789 79,075
Diluted (in shares) 90,168 79,413 89,305 79,075

Source